ArticleOncotarget2016
Paradoxical overexpression of MBNL2 in hepatocellular carcinoma inhibits tumor growth and invasion.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 18 citations in OpenAlex.
- MBNL proteins in health, disease, and therapeutic applications.Nucleic acids research · 2026Review
- Multi-omics identification of MBNL2 associated with poor pathological response to neoadjuvant chemoimmunotherapy in lung squamous cell carcinoma.Frontiers in oncology · 2026Article
- The role of genetic variation in shaping phenotypic responses to diet in aging Drosophila melanogaster.Heredity · 2025Article
- A novel prognostic risk score associated with resistance to docetaxel chemotherapy for predicting biochemical recurrence-free survival in patients with prostate cancer.Discover oncology · 2025Article
- MBNL2 enhances cisplatin resistance by regulating apoptosis in ovarian cancer cells.BMB reports · 2025Article
- Expression profile, regulatory mechanism and prognostic potential of MBNL2 in esophageal squamous cell carcinoma.Translational cancer research · 2025Article
- ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo.Cancers · 2022Article
- RNA splicing: a dual-edged sword for hepatocellular carcinoma.Medical oncology (Northwood, London, England) · 2022Review
- Transcriptome analysis of clock disrupted cancer cells reveals differential alternative splicing of cancer hallmarks genes.NPJ systems biology and applications · 2022Article
- Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer.Frontiers in genetics · 2022Article
- Identification and validation of a signature based on macrophage cell marker genes to predict recurrent miscarriage by integrated analysis of single-cell and bulk RNA-sequencing.Frontiers in immunology · 2022Article
- MBNL2 Regulates DNA Damage Response via Stabilizing p21.International journal of molecular sciences · 2021Article
- Competitive Endogenous RNA Landscape in Epstein-Barr Virus Associated Nasopharyngeal Carcinoma.Frontiers in cell and developmental biology · 2021Article
- RNA-binding Protein MBNL2 regulates Cancer Cell Metastasis through MiR-182-MBNL2-AKT Pathway.Journal of Cancer · 2021Article
- Muscleblind-like 2 controls the hypoxia response of cancer cells.RNA (New York, N.Y.) · 2020Article
- Identifying the key genes and microRNAs in prostate cancer bone metastasis by bioinformatics analysis.FEBS open bio · 2020Article
- The natural compound neobractatin inhibits tumor metastasis by upregulating the RNA-binding-protein MBNL2.Cell death & disease · 2019Article
- Messenger RNA Life-Cycle in Cancer Cells: Emerging Role of Conventional and Non-Conventional RNA-Binding Proteins?International journal of molecular sciences · 2018Review
- Alternative RNA Splicing in the Pathogenesis of Liver Disease.Frontiers in endocrinology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pre-mRNA alternative splicing is an essential step in the process of gene expression. It provides cells with the opportunity to create various protein isoforms. Disruptions of alternative splicing are associated with various diseases, including cancer. The muscleblind-like (MBNL) protein is a splicing regulatory protein. Overexpression of MBNL proteins in embryonic stem cells promotes differentiated cell-like alternative splicing patterns. We examined the expression level of MBNL2 in 143 resected HCCs using immunohistochemistry. MBNL2 was overexpressed in 51 (35.7%) HCCs. The overexpression of MBNL2 correlated with smaller tumor size (≤ 3 cm, P = 0.0108) and low tumor stage (Stage I, P = 0.0026), indicating that MBNL2 expression was lost in the late stage of HCC development. Furthermore, patients with MBNL2-positive HCCs had a borderline better 5-year overall survival (P = 0.0579). In non-cancerous liver parenchyma, MBNL2 was stained on the Canals of Hering and hepatocytes newly derived from hepatic progenitor cells. The overexpression of MBNL2 in Hep-J5 cells suppressed proliferation, tumorsphere formation, migration, and in vitro invasion, and also reduced in vivo tumor growth in NOD/SCID mice. In contrast, MBNL2 depletion with RNA interference in Huh7 cells increased in vitro migration and invasion, but did not enhance tumor growth. These results indicate that MBNL2 is a tumor suppressor in hepatocarcinogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.